Novavax, a biotech firm based mostly in Maryland, introduced as we speak that its two-dose vaccine was 96% efficient in opposition to the unique Covid-19 vaccine, although it was much less efficient in opposition to variants.
The company says that the vaccine is 96% efficient at defending in opposition to gentle, reasonable and extreme illness brought on by the unique Covid-19 virus, which makes it barely extra protecting than the Moderna or Pfizer-BioNTech vaccines.
It is 86% efficient in opposition to the B.1.1.7 virus that was first found within the U.Okay., however solely 55% efficient in opposition to the B1.351 variant first found in South Africa.
Regardless of the variant, nobody within the scientific trials who obtained the Novavax vaccine was hospitalized with extreme Covid-19 or died from the illness.
The firm has already inked offers with nations together with Canada, the U.Okay., Australia and India and expects to have the capability to fabricate 2 billion doses by mid-2021.
The Novavax vaccine is completely different from the mRNA vaccines and the single-dose Johnson & Johnson vaccine which have already been approved within the U.S. This vaccine is made up of nanoparticles that mimic the Covid-19 spike protein. When injected, immune cells within the physique react to the vaccine and create antibodies that may block the SARS-Cov-2 virus if the physique will get contaminated sooner or later. The nanoparticle vaccine can’t make you sick or provide you with Covid-19.
What To Watch For
The subsequent step for the corporate shall be to use for Emergency Use Authorization from the FDA. In its current earnings report, Novavax stated that it’s in ongoing conversations with the FDA and will file for an EUA as early as Q2 2021.
95.7 million. That’s what number of doses of Covid-19 vaccines have been administered to date within the U.S.
Full protection and reside updates on the Coronavirus